Kalaris Therapeutics (KLRS) Interest Coverage Ratio (2019 - 2026)
Kalaris Therapeutics (KLRS) posted quarterly Interest Coverage Ratio of 2.56 for Q1 2026, down 1002.22% year-over-year from 0.28 in Q1 2025, and down 17.8% quarter-over-quarter from 2.17 in Q3 2025.
Kalaris Therapeutics (KLRS) Interest Coverage Ratio (2019 - 2026) Analysis & Trends
Kalaris Therapeutics' Interest Coverage Ratio history runs 8 years deep, the most recent figure standing at 2.56 for Q1 2026.
- In Q1 2026, Interest Coverage Ratio fell 1002.22% year-over-year to 2.56; the TTM figure through Mar 2026 stood at 10.29 (down 671.77% YoY), while the FY2025 annual figure was 4.83, down 119.18% from the prior year.
- Interest Coverage Ratio for Q1 2026 stood at 2.56, down from 2.17 in the prior quarter.
- The five-year high for Interest Coverage Ratio was 0.23 in Q1 2025, with the low at 69.34 in Q4 2023.
- The 5-year median for Interest Coverage Ratio is 18.74 (2023), against an average of 24.04.
- The sharpest annual moves came in 2022 and 2025: Interest Coverage Ratio tumbled 2770.86% in 2022, then jumped 99.1% in 2025.
- Kalaris Therapeutics' Interest Coverage Ratio stood at 25.27 in 2022, then tumbled by 174.38% to 69.34 in 2023, then jumped by 92.14% to 5.45 in 2024, then soared by 60.2% to 2.17 in 2025, then declined by 17.8% to 2.56 in 2026.
- Business Quant data shows KLRS's Interest Coverage Ratio at 2.56 in Q1 2026, 2.17 in Q3 2025, and 5.76 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Interest Cover (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.84 Bn | 131.99 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.48 Bn | 78.49 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.15 Bn | 55.01 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.22 Bn | 37.12 Bn | 1.53 Bn | 8.18 |
| 6 | Alnylam Pharmaceuticals | 31.67 Bn | 28.36 Bn | 992.69 Mn | 2.82 |
| 7 | BioNTech SE | 28.54 Bn | 10.14 Bn | 668.28 Mn | 76.86 |
| 8 | Insmed | 27.58 Bn | 26.42 Bn | 358.27 Mn | -0.08 |
| 9 | Royalty Pharma | 27.22 Bn | 26.38 Bn | - | 1.42 |
| 10 | Kalaris Therapeutics | 99.00 Mn | 99.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.65 |
| Mar 31, 2026 | -2.56 |
| Sep 30, 2025 | -2.17 |
| Jun 30, 2025 | -5.76 |
| Mar 31, 2025 | -0.23 |
| Dec 31, 2024 | -5.45 |
| Sep 30, 2024 | -46.44 |
| Jun 30, 2024 | -8.39 |
| Mar 31, 2024 | -25.63 |
| Dec 31, 2023 | -69.34 |
| Sep 30, 2023 | -58.70 |
| Jun 30, 2023 | -16.89 |
| Mar 31, 2023 | -20.59 |
| Dec 31, 2022 | -25.27 |
| Sep 30, 2022 | -11.68 |
| Jun 30, 2022 | -49.58 |
| Mar 31, 2022 | -35.99 |
| Dec 31, 2021 | -34.87 |
| Sep 30, 2021 | -1.44 |
| Jun 30, 2021 | -3.35 |